A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Profile

A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs APL 2 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Acronyms PADDOCK
  • Sponsors Apellis Pharmaceuticals
  • Most Recent Events

    • 29 Jun 2017 Results (n=3; 270mg dose) published in an Apellis Pharmaceuticals media release.
    • 26 Jan 2017 Status changed from active, no longer recruiting to recruiting.
    • 02 Dec 2016 Interim results will be presented at the International PNH Interest Group (IPIG) Annual Scientific Assembly and at the American Society of Hematology (ASH) Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top